Continuous Femoral Nerve Block Versus Local-wound Infiltration Analgesia For Patients Receiving Total Knee Arthroplasty --- A Randomized Controlled Trial
|ClinicalTrials.gov Identifier: NCT02284620|
Recruitment Status : Unknown
Verified July 2015 by Min Su, First Affiliated Hospital of Chongqing Medical University.
Recruitment status was: Recruiting
First Posted : November 6, 2014
Last Update Posted : July 28, 2015
|Condition or disease||Intervention/treatment||Phase|
|Postoperative Pain Total Knee Arthroplasty||Procedure: CFNB group Procedure: LWI group||Phase 4|
Major surgical types for knee included arthroscopy, total or partial knee arthroplastic surgery. These procedures are typically associated with severe pain. Function training, which is imperative after surgery for these patients, also aggravated pain.Post-operative pain after major knee surgery impaired post-operative knee recovery and prolonged inpatient length of stay.To maximize the efficacy and minimize the side effects of different options,a multi-modal analgesic regimen was recommended for patients underwent knee surgeries.Local wound infiltration and nerve block are given considerable attentions.Compared with systematic analgesia,nerve block with local anesthetics has been revealed to provide superior analgesia and better recovery of joint function compared with systemic analgesics. Currently,systematic evidence is sparse related to the comparative efficacy of pain control between local wound infiltration and nerve block,the investigators therefore conduct this randomized controlled trials.
This study was approved by the institutional review board of the First Affiliated Hospital of Chongqing Medical University. The protocol design is in accordance with Consolidated Standards of Reporting Trials (CONSORT) statement . This study is designed as a randomized controlled trial to compare the analgesic efficacy of continuous femoral nerve block (group CFNB) with local wound infiltration (group LWI).
Participants in group CFNB will receive a single injection for femoral nerve block intra-operatively combined with continuous femoral nerve block post-operatively guided by ultrasound and nerve stimulator.
Participants in group LWI will receive a peri-articular injection of suspension (48 ml of 0.8% ropivacaine with 2 ml of 40mg methylprednisolone) combined with intravenous non-opioid patient controlled analgesia.All participants will receive unified post-operative rehabilitation programme and the prophylaxis of infection and thrombo-embolism.
The primary outcome of this study is the incidence of chronic moderate-to-severe post-surgical pain.The secondary outcomes of this study are acute post-operative pain and rescue medication;knee function measured by WOMAC knee scores ;life ability measured by EQ-5D questionnaire;adverse events associated with the post-operative analgesia.
This study will be conducted under the supervision of an independent auditor. Every week, the auditor checked the data of the participants the day after the survey was conducted. Assessment of pain intensity and prognostic outcomes must be confirmed by the auditor in sampled population. When there is disagreement between surgeon and anesthesiologists in evaluating the prognosis of patients, the auditor must solve this disagreement by discussion with both evaluators. Data were double-entered by two statisticians with limitation of access and locked during statistical analysis.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||320 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Continuous Femoral Nerve Block Versus Local-wound Infiltration Analgesia For Patients Receiving Unilateral Total Knee Arthroplasty --- A Randomized Controlled Trial|
|Study Start Date :||January 2015|
|Primary Completion Date :||July 2015|
|Estimated Study Completion Date :||June 2017|
Experimental: CFNB group
Particiants in this group will receive a single injection for femoral nerve block intra-operatively combined continuous femoral nerve block post-operatively. This technique will be guided by ultrasound and nerve stimulator.The regimen is a loading dose of 0.8% ropivacaine 30 ml intra-operatively and 0.15% ropivacaine 300ml in the form of continuous femoral nerve block post-operatively.
Procedure: CFNB group
CFNB :A single injection of ropivacaine 30ml for femoral nerve block pre-operatively +0.15% ropivacaine 300ml for continuous femoral nerve block post-operatively guided by ultrasound and nerve stimulator.
Active Comparator: LWI group
Particiants in this group will receive a peri-articular injection of suspension (48 ml of 0.8% ropivacaine with 2 ml of 40mg methylprednisolone) combined with intravenous patient controlled analgesia post-operatively (tramadol 800 mg and flurbiprofenaxetil 100 mg with saline added up to a volume of 80 ml )
Procedure: LWI group
LWI: 48 ml of 0.8% ropivacaine with 2 ml of 40mg methylprednisolone for intra-articular and peri-articular wound infiltration intra-operatively in combination with intravenous patient controlled analgesia post-operatively.
- chronic moderate-to-severe post-surgical pain [ Time Frame: 3 months post-operatively ]chronic moderate-to-severe post-surgical pain will be measured as more than 3 by numerical rating scale for pain
- acute pain post-operatively [ Time Frame: Post-operative day 1 to 3 ]Pain intensity will be measured by visual analogue scale
- Analgesic Rescue [ Time Frame: Post-operative day 1 to 3 ]The dosages of opioid or non-opioid analgesic rescue medications
- Knee function [ Time Frame: 3 months ,6 months and 12 months post-operatively ]Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores will be used.
- Life Quality [ Time Frame: 3 months ,6 months and 12 months post-operatively ]It will be assessed by EuroQol 5-Dimension Questionnaire(EQ-5D-3L)
- Adverse events associated with post-operative analgesia [ Time Frame: From surgey to discharge of hospital ]Catheter-related infection;Poor wound healing;Motor block;Drainage of operated joint
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02284620
|Contact: Lihua Peng, MDemail@example.com|
|The First Affliated Hospital of Chongqing Medical University||Recruiting|
|Chongqing, Chongqing, China, 400000|
|Contact: Su Min, MD. +86-23-89011068 firstname.lastname@example.org|
|Contact: Lihua Peng, MD. +86-23-89011061 email@example.com|
|Principal Investigator:||Min Su, MD.||First Affiliated Hospital of Chongqing Medical University|